 Ronald Vagnozzi
Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocytes, Cardiac | 20 | 2023 | 457 | 3.790 |
Why?
| | Cell- and Tissue-Based Therapy | 2 | 2021 | 57 | 1.420 |
Why?
| | Stem Cell Transplantation | 2 | 2021 | 151 | 1.350 |
Why?
| | Ventricular Remodeling | 10 | 2023 | 227 | 1.270 |
Why?
| | Adult Stem Cells | 2 | 2018 | 32 | 1.250 |
Why?
| | Myocardial Infarction | 8 | 2019 | 931 | 1.230 |
Why?
| | Immunity, Innate | 3 | 2021 | 731 | 1.090 |
Why?
| | Myocardium | 9 | 2023 | 926 | 1.040 |
Why?
| | Macrophages | 7 | 2023 | 1284 | 0.940 |
Why?
| | Cell Differentiation | 7 | 2020 | 1700 | 0.910 |
Why?
| | Cardiomyopathies | 3 | 2023 | 303 | 0.880 |
Why?
| | Homeostasis | 3 | 2021 | 577 | 0.870 |
Why?
| | T-Lymphocytes | 2 | 2022 | 1756 | 0.860 |
Why?
| | Sirtuin 3 | 1 | 2023 | 52 | 0.850 |
Why?
| | Heart | 5 | 2020 | 610 | 0.840 |
Why?
| | Cardiomyopathy, Restrictive | 1 | 2021 | 9 | 0.780 |
Why?
| | Monocytes | 2 | 2020 | 507 | 0.740 |
Why?
| | Immunity, Humoral | 1 | 2021 | 112 | 0.710 |
Why?
| | Fibrosis | 9 | 2023 | 457 | 0.700 |
Why?
| | Myocarditis | 1 | 2021 | 94 | 0.700 |
Why?
| | Myeloid Cells | 1 | 2020 | 127 | 0.680 |
Why?
| | Immunity, Cellular | 1 | 2021 | 262 | 0.670 |
Why?
| | Antigens, Ly | 1 | 2018 | 45 | 0.650 |
Why?
| | Myofibroblasts | 5 | 2021 | 116 | 0.640 |
Why?
| | Running | 1 | 2020 | 209 | 0.620 |
Why?
| | Myocardial Ischemia | 3 | 2015 | 237 | 0.610 |
Why?
| | Immunotherapy | 1 | 2022 | 479 | 0.610 |
Why?
| | Congresses as Topic | 1 | 2019 | 204 | 0.610 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 194 | 0.590 |
Why?
| | Mice | 29 | 2023 | 15052 | 0.590 |
Why?
| | Animals | 38 | 2023 | 32104 | 0.580 |
Why?
| | Glycogen Synthase Kinase 3 | 5 | 2014 | 77 | 0.520 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 630 | 0.510 |
Why?
| | Membrane Proteins | 2 | 2018 | 1024 | 0.510 |
Why?
| | Stem Cells | 1 | 2019 | 546 | 0.500 |
Why?
| | Disease Models, Animal | 11 | 2021 | 3580 | 0.470 |
Why?
| | Cardiovascular Diseases | 3 | 2023 | 1729 | 0.460 |
Why?
| | Extracellular Matrix | 6 | 2021 | 439 | 0.460 |
Why?
| | Biomedical Research | 1 | 2019 | 589 | 0.450 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2013 | 68 | 0.440 |
Why?
| | Endothelium, Vascular | 2 | 2018 | 847 | 0.430 |
Why?
| | Protein Kinases | 1 | 2013 | 306 | 0.390 |
Why?
| | Aging | 5 | 2020 | 1632 | 0.380 |
Why?
| | Gene Deletion | 5 | 2017 | 355 | 0.370 |
Why?
| | Rodentia | 2 | 2021 | 44 | 0.370 |
Why?
| | Mice, Transgenic | 10 | 2023 | 1970 | 0.360 |
Why?
| | Fibroblasts | 3 | 2022 | 839 | 0.360 |
Why?
| | Mice, Inbred C57BL | 13 | 2020 | 4773 | 0.330 |
Why?
| | Regeneration | 4 | 2020 | 162 | 0.320 |
Why?
| | Cell Lineage | 4 | 2020 | 310 | 0.320 |
Why?
| | Mitochondria | 5 | 2020 | 750 | 0.310 |
Why?
| | Coronary Vessels | 2 | 2021 | 230 | 0.300 |
Why?
| | Oxidative Stress | 1 | 2013 | 1093 | 0.290 |
Why?
| | Myocardial Contraction | 4 | 2015 | 315 | 0.270 |
Why?
| | Signal Transduction | 6 | 2021 | 4541 | 0.240 |
Why?
| | Heart Diseases | 2 | 2017 | 331 | 0.230 |
Why?
| | Chordata | 1 | 2023 | 5 | 0.230 |
Why?
| | Calcium Channels | 2 | 2015 | 146 | 0.220 |
Why?
| | Iron-Binding Proteins | 1 | 2023 | 39 | 0.220 |
Why?
| | Calcium | 3 | 2015 | 1103 | 0.220 |
Why?
| | Heart Failure | 4 | 2023 | 1964 | 0.220 |
Why?
| | Bone Marrow Transplantation | 2 | 2021 | 239 | 0.220 |
Why?
| | Collagen Type I | 1 | 2023 | 110 | 0.210 |
Why?
| | Mitochondrial Membrane Transport Proteins | 2 | 2013 | 29 | 0.210 |
Why?
| | Arteries | 2 | 2023 | 250 | 0.210 |
Why?
| | Ventricular Dysfunction, Left | 3 | 2014 | 366 | 0.200 |
Why?
| | Cells, Cultured | 7 | 2018 | 3914 | 0.200 |
Why?
| | Phagocytes | 1 | 2021 | 92 | 0.180 |
Why?
| | Arteritis | 1 | 2020 | 27 | 0.180 |
Why?
| | Bone Marrow Cells | 1 | 2021 | 268 | 0.180 |
Why?
| | Smad3 Protein | 2 | 2017 | 41 | 0.180 |
Why?
| | Treatment Failure | 1 | 2021 | 332 | 0.180 |
Why?
| | Gene Transfer Techniques | 1 | 2021 | 148 | 0.180 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2021 | 132 | 0.170 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 174 | 0.170 |
Why?
| | Rejuvenation | 1 | 2019 | 14 | 0.170 |
Why?
| | Marfan Syndrome | 1 | 2020 | 43 | 0.170 |
Why?
| | HSP47 Heat-Shock Proteins | 1 | 2019 | 4 | 0.170 |
Why?
| | STAT3 Transcription Factor | 1 | 2021 | 174 | 0.170 |
Why?
| | Collagen | 2 | 2019 | 416 | 0.170 |
Why?
| | Boston | 1 | 2019 | 74 | 0.170 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2019 | 12 | 0.170 |
Why?
| | Cell Communication | 1 | 2021 | 282 | 0.170 |
Why?
| | Injections | 1 | 2020 | 161 | 0.170 |
Why?
| | Genetic Engineering | 1 | 2019 | 81 | 0.160 |
Why?
| | Cell Adhesion Molecules | 2 | 2020 | 168 | 0.160 |
Why?
| | Myoblasts, Cardiac | 2 | 2018 | 3 | 0.160 |
Why?
| | Vascular Remodeling | 2 | 2021 | 155 | 0.160 |
Why?
| | Cell Movement | 3 | 2018 | 867 | 0.160 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 376 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 1 | 2021 | 501 | 0.160 |
Why?
| | Muscle Development | 1 | 2018 | 93 | 0.150 |
Why?
| | Ischemia | 1 | 2021 | 363 | 0.150 |
Why?
| | Yolk Sac | 1 | 2018 | 5 | 0.150 |
Why?
| | Cell Self Renewal | 1 | 2018 | 49 | 0.150 |
Why?
| | Regenerative Medicine | 1 | 2018 | 41 | 0.150 |
Why?
| | Heart Valve Diseases | 1 | 2020 | 159 | 0.150 |
Why?
| | Cicatrix | 1 | 2018 | 50 | 0.150 |
Why?
| | Smad2 Protein | 1 | 2017 | 33 | 0.150 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 31 | 0.150 |
Why?
| | Nanoparticles | 1 | 2021 | 315 | 0.150 |
Why?
| | Cardiomegaly | 4 | 2023 | 161 | 0.150 |
Why?
| | Embryonic Stem Cells | 1 | 2018 | 105 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-kit | 2 | 2014 | 63 | 0.140 |
Why?
| | Models, Animal | 1 | 2018 | 350 | 0.140 |
Why?
| | RNA, Messenger | 2 | 2022 | 2574 | 0.140 |
Why?
| | Actin Cytoskeleton | 2 | 2015 | 93 | 0.140 |
Why?
| | Dual-Specificity Phosphatases | 1 | 2016 | 10 | 0.140 |
Why?
| | Humans | 16 | 2023 | 115739 | 0.130 |
Why?
| | Isoproterenol | 1 | 2016 | 110 | 0.130 |
Why?
| | Mice, Knockout | 7 | 2018 | 2604 | 0.130 |
Why?
| | Cellular Reprogramming | 1 | 2016 | 84 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2013 | 790 | 0.130 |
Why?
| | Chronic Disease | 1 | 2021 | 1598 | 0.130 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 64 | 0.130 |
Why?
| | Male | 13 | 2021 | 56048 | 0.130 |
Why?
| | Aorta, Thoracic | 2 | 2015 | 262 | 0.130 |
Why?
| | Enzyme Activation | 2 | 2014 | 793 | 0.120 |
Why?
| | Muscle Proteins | 1 | 2016 | 209 | 0.120 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 446 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 275 | 0.120 |
Why?
| | Heart Ventricles | 1 | 2019 | 722 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2015 | 339 | 0.120 |
Why?
| | Melanosomes | 1 | 2014 | 2 | 0.120 |
Why?
| | Aortic Diseases | 1 | 2015 | 111 | 0.120 |
Why?
| | Concanavalin A | 1 | 2014 | 75 | 0.120 |
Why?
| | Pigment Epithelium of Eye | 1 | 2014 | 34 | 0.110 |
Why?
| | Heart Injuries | 1 | 2014 | 36 | 0.110 |
Why?
| | Niacinamide | 1 | 2014 | 65 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2016 | 553 | 0.110 |
Why?
| | Phenylurea Compounds | 1 | 2014 | 83 | 0.110 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2013 | 93 | 0.110 |
Why?
| | Small Molecule Libraries | 1 | 2013 | 81 | 0.110 |
Why?
| | Superoxides | 1 | 2013 | 215 | 0.110 |
Why?
| | Cation Transport Proteins | 1 | 2013 | 123 | 0.110 |
Why?
| | Cell Proliferation | 5 | 2020 | 2194 | 0.100 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 263 | 0.100 |
Why?
| | Calcium-Binding Proteins | 1 | 2013 | 203 | 0.100 |
Why?
| | Heart Rupture | 1 | 2011 | 4 | 0.100 |
Why?
| | Cell Death | 1 | 2013 | 326 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2015 | 342 | 0.100 |
Why?
| | Sarcopenia | 1 | 2013 | 64 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2021 | 9162 | 0.090 |
Why?
| | Indoles | 2 | 2013 | 309 | 0.090 |
Why?
| | Cyclophilins | 1 | 2010 | 29 | 0.090 |
Why?
| | Up-Regulation | 1 | 2013 | 820 | 0.090 |
Why?
| | Acute Coronary Syndrome | 1 | 2013 | 254 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1754 | 0.090 |
Why?
| | Female | 6 | 2021 | 60016 | 0.080 |
Why?
| | Energy Metabolism | 1 | 2013 | 715 | 0.080 |
Why?
| | Pyrroles | 1 | 2009 | 185 | 0.070 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2009 | 175 | 0.070 |
Why?
| | Endothelial Cells | 3 | 2019 | 696 | 0.070 |
Why?
| | Primary Cell Culture | 2 | 2019 | 149 | 0.070 |
Why?
| | Animals, Newborn | 2 | 2020 | 780 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 2 | 2020 | 346 | 0.070 |
Why?
| | Cell Fusion | 2 | 2016 | 50 | 0.060 |
Why?
| | Inflammation | 1 | 2015 | 2500 | 0.060 |
Why?
| | Lipoylation | 1 | 2023 | 16 | 0.060 |
Why?
| | Histidine | 1 | 2023 | 57 | 0.060 |
Why?
| | Acyltransferases | 1 | 2023 | 46 | 0.060 |
Why?
| | Echocardiography | 2 | 2021 | 562 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1537 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2014 | 1893 | 0.050 |
Why?
| | Rats | 3 | 2019 | 5033 | 0.050 |
Why?
| | Heart Atria | 1 | 2023 | 111 | 0.050 |
Why?
| | Acclimatization | 1 | 2023 | 132 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2013 | 55 | 0.050 |
Why?
| | Theranostic Nanomedicine | 1 | 2021 | 8 | 0.050 |
Why?
| | Airway Remodeling | 1 | 2021 | 60 | 0.050 |
Why?
| | Disease Progression | 2 | 2020 | 2423 | 0.050 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 2 | 2013 | 99 | 0.050 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2021 | 142 | 0.050 |
Why?
| | Transplantation Chimera | 1 | 2020 | 51 | 0.050 |
Why?
| | Drug Carriers | 1 | 2021 | 113 | 0.040 |
Why?
| | Hypertrophy | 1 | 2020 | 110 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 171 | 0.040 |
Why?
| | Fibrillin-1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Angiotensin II | 1 | 2020 | 91 | 0.040 |
Why?
| | Leukocyte Common Antigens | 1 | 2020 | 76 | 0.040 |
Why?
| | Multiprotein Complexes | 2 | 2013 | 145 | 0.040 |
Why?
| | Zebrafish | 1 | 2023 | 412 | 0.040 |
Why?
| | Sarcoglycans | 1 | 2019 | 4 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2020 | 105 | 0.040 |
Why?
| | Genetic Therapy | 1 | 2021 | 260 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Mitral Valve | 1 | 2020 | 85 | 0.040 |
Why?
| | Bone Marrow | 1 | 2020 | 249 | 0.040 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 188 | 0.040 |
Why?
| | Dogs | 1 | 2020 | 341 | 0.040 |
Why?
| | Epigenesis, Genetic | 1 | 2023 | 526 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 301 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2013 | 362 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 391 | 0.040 |
Why?
| | Blood Circulation | 1 | 2018 | 35 | 0.040 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 52 | 0.040 |
Why?
| | Swine | 1 | 2020 | 706 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2019 | 1447 | 0.040 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 214 | 0.040 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 127 | 0.040 |
Why?
| | Mice, Inbred mdx | 1 | 2016 | 11 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2353 | 0.040 |
Why?
| | Organ Specificity | 1 | 2017 | 273 | 0.040 |
Why?
| | Microscopy, Confocal | 1 | 2018 | 299 | 0.030 |
Why?
| | Phenotype | 2 | 2015 | 2839 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6171 | 0.030 |
Why?
| | Mice, 129 Strain | 1 | 2016 | 77 | 0.030 |
Why?
| | Catecholamines | 1 | 2016 | 97 | 0.030 |
Why?
| | Protein Phosphatase 2C | 1 | 2015 | 14 | 0.030 |
Why?
| | Ventricular Myosins | 1 | 2015 | 33 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2015 | 47 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2015 | 81 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 794 | 0.030 |
Why?
| | Myofibrils | 1 | 2015 | 46 | 0.030 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2016 | 169 | 0.030 |
Why?
| | Plaque, Atherosclerotic | 1 | 2015 | 44 | 0.030 |
Why?
| | Sarcomeres | 1 | 2015 | 89 | 0.030 |
Why?
| | Apoptosis | 2 | 2014 | 2377 | 0.030 |
Why?
| | Proteins | 2 | 2013 | 920 | 0.030 |
Why?
| | Microfilament Proteins | 1 | 2015 | 126 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 1 | 2014 | 119 | 0.030 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2014 | 60 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2015 | 225 | 0.030 |
Why?
| | Cytoplasmic Streaming | 1 | 2014 | 2 | 0.030 |
Why?
| | Cell Aggregation | 1 | 2014 | 24 | 0.030 |
Why?
| | Metoprolol | 1 | 2014 | 37 | 0.030 |
Why?
| | Perciformes | 1 | 2014 | 17 | 0.030 |
Why?
| | Cats | 1 | 2014 | 204 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2651 | 0.030 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 239 | 0.030 |
Why?
| | Integrases | 1 | 2014 | 117 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2013 | 198 | 0.030 |
Why?
| | Maleimides | 1 | 2013 | 24 | 0.030 |
Why?
| | Tamoxifen | 1 | 2014 | 192 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 431 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2015 | 420 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 63 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2013 | 160 | 0.030 |
Why?
| | HeLa Cells | 1 | 2013 | 567 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2014 | 1044 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2015 | 399 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 544 | 0.020 |
Why?
| | Hepatocytes | 1 | 2013 | 197 | 0.020 |
Why?
| | Sirolimus | 1 | 2013 | 192 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2013 | 153 | 0.020 |
Why?
| | Phosphorylation | 1 | 2015 | 1571 | 0.020 |
Why?
| | Cardiotonic Agents | 1 | 2011 | 119 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 3471 | 0.020 |
Why?
| | Death | 1 | 2011 | 109 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 174 | 0.020 |
Why?
| | Autophagy | 1 | 2013 | 236 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 816 | 0.020 |
Why?
| | Binding Sites | 1 | 2013 | 1177 | 0.020 |
Why?
| | Mitochondria, Heart | 1 | 2010 | 73 | 0.020 |
Why?
| | Bone and Bones | 1 | 2013 | 283 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1642 | 0.020 |
Why?
| | Knee Joint | 1 | 2013 | 325 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1870 | 0.020 |
Why?
| | Exons | 1 | 2010 | 300 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2009 | 77 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2010 | 185 | 0.020 |
Why?
| | Myosin Heavy Chains | 1 | 2010 | 169 | 0.020 |
Why?
| | Capillaries | 1 | 2009 | 92 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 1917 | 0.020 |
Why?
| | Cell Division | 1 | 2010 | 759 | 0.020 |
Why?
| | DNA | 1 | 2014 | 1356 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1646 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2010 | 1122 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1024 | 0.020 |
Why?
| | Biopsy | 1 | 2009 | 1056 | 0.020 |
Why?
| | Liver | 1 | 2013 | 1690 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2009 | 2262 | 0.010 |
Why?
| | Adult | 1 | 2023 | 30788 | 0.010 |
Why?
| | Transcription Factors | 1 | 2009 | 1528 | 0.010 |
Why?
| | Aged | 1 | 2014 | 19294 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 27069 | 0.010 |
Why?
|
|
Vagnozzi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|